Ignite Creation Date:
2025-12-25 @ 4:31 AM
Ignite Modification Date:
2026-02-02 @ 1:38 AM
Study NCT ID:
NCT06235918
Status:
RECRUITING
Last Update Posted:
2024-02-01
First Post:
2024-01-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Sponsor:
Organization: